Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Executive Summary
CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.
You may also be interested in...
Product Differences Necessitate Some US FDA Inconsistency In Rare Diseases, Center Directors Say
Development standards for a one-time gene therapy should be different from a drug taken regularly, CBER Director Peter Marks says.
US FDA’s Accelerated Approval Reforms Include Dispute Resolution For Withdrawals
Allowing decisions to be reviewed by higher management levels, rather than convening administrative hearings, could save time in the withdrawal process.
CMS Input On Pivotal Trials Could Anticipate Medicare Coverage Issues – Brooks-LaSure
Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure responds to US Congressional concerns about the proposed Medicare coverage policy for Alzheimer’s drugs.